JP Morgan Chase
ACTU

JP Morgan Chase’s Actuate Therapeutics ACTU Stock Holding History

JP Morgan Chase’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12K Buy
7,626
+3,763
+97% +$8.72K ﹤0.01% 6865
2026
Q1 		$8.85K Buy
3,863
+68
+2% +$282 ﹤0.01% 6771
2025
Q4 		$23.2K Buy
3,795
+1,311
+53% +$9.01K ﹤0.01% 6467
2025
Q3 		$16.6K Sell
2,484
-296
-11% -$2.15K ﹤0.01% 6520
2025
Q2 		$17K Buy
+2,780
New +$24.3K ﹤0.01% 6210
2025
Q1 		– Sell
-3
Closed -$24 – 7817
2024
Q4 		$24 Buy
+3
New +$24 ﹤0.01% 7247

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

JP Morgan Chase's ACTU Position: Q2 2026 in Review

JP Morgan Chase increased its Actuate Therapeutics (ACTU) stake by 97% in Q2 2026, buying an estimated $8.72K and bringing the position to 7,626 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #6865.

JP Morgan Chase first reported a position in ACTU in Q4 2024 and has held it in 6 quarters since. The position peaked at $23.2K in Q4 2025. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • JP Morgan Chase held 7,626 shares of Actuate Therapeutics worth $12K as of Q2 2026.
  • JP Morgan Chase bought 3,763 Actuate Therapeutics shares in Q2 2026, an estimated $8.72K.
  • Actuate Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6865 holding.
  • JP Morgan Chase first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • JP Morgan Chase's Actuate Therapeutics position peaked at $23.2K in Q4 2025.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.